Further improvement in EBIT margin
Focusing on system- and time-critical components for long-term growth markets has allowed Datwyler to fur-ther improve its profitability. The operating result (EBIT) thus rose by 13.2% to CHF 90.7 million (previous year: CHF 80.1 million). The EBIT margin improved further to reach 13.1% (previous year: 12.4%). Drawing on its operational strength, Datwyler was able to offset higher raw material prices and set-up costs associated with growth projects. The net result improved by 17.3% to CHF 62.5 million (previous year: CHF 53.3 million). Con-struction work on the new Health Care plant in the USA saw investments increase to CHF 71.7 million during the first half of the year (previous year: CHF 37.7 million). When this new US plant opens in the second half of 2018, Datwyler will be well positioned to profit from the rapid rise in demand for high-quality components for prefilled syringes and other modern drug delivery systems.
The Datwyler Group has maintained its profitable growth path in the first half of 2018. The healthy order book in the key market segments of Health Care and Automotive as well as some promising acquisition projects should generate additional momentum in the second half of the year.CEO Dirk Lambrecht